Evidence map›Paper›PMID 31241222›Full record

ArticleHuman mutation2019

Assessing the performance of in silico methods for predicting the pathogenicity of variants in the gene CHEK2, among Hispanic females with breast cancer.

Alin Voskanian, Panagiotis Katsonis, Olivier Lichtarge, Vikas Pejaver, Predrag Radivojac, Sean D Mooney, Emidio Capriotti, Yana Bromberg, Yanran Wang, Max Miller and 19 more

Abstract read
In one paragraph

Article in Human mutation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Alin VoskanianDepartment of Biological Sciences, University of Maryland, Baltimore, Maryland.ORCID 0000-0003-2000-9574
Panagiotis KatsonisDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas.ORCID 0000-0002-7172-1644
Olivier LichtargeDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas.
Vikas PejaverDepartment of Biomedical Informatics and Medical Education, University of Washington, Seattle, Washington.ORCID 0000-0002-1943-0284
Predrag RadivojacKhoury College of Computer and Information Sciences, Northeastern University, Boston, Massachusetts.ORCID 0000-0002-6769-0793
Sean D MooneyDepartment of Biomedical Informatics and Medical Education, University of Washington, Seattle, Washington.ORCID 0000-0003-2654-0833
Emidio CapriottiBioFolD Unit, Department of Pharmacy and Biotechnology (FaBiT), University of Bologna, Bologna, Italy.
Yana BrombergDepartment of Biochemistry and Microbiology, Rutgers University, New Brunswick, New Jersey.
Yanran WangDepartment of Biochemistry and Microbiology, Rutgers University, New Brunswick, New Jersey.
Max MillerDepartment of Biochemistry and Microbiology, Rutgers University, New Brunswick, New Jersey.ORCID 0000-0002-1335-9499
Pier Luigi MartelliBiocomputing Group, BiGeA/Giorgio Prodi Interdepartmental Center for Cancer Research, University of Bologna, Bologna, Italy.
Castrense SavojardoBiocomputing Group, BiGeA/Giorgio Prodi Interdepartmental Center for Cancer Research, University of Bologna, Bologna, Italy.
Giulia BabbiBiocomputing Group, BiGeA/Giorgio Prodi Interdepartmental Center for Cancer Research, University of Bologna, Bologna, Italy.
Rita CasadioBiocomputing Group, BiGeA/Giorgio Prodi Interdepartmental Center for Cancer Research, University of Bologna, Bologna, Italy.
Yue CaoDepartment of Electrical and Computer Engineering, Texas A&M University, College Station, Texas.
Yuanfei SunDepartment of Electrical and Computer Engineering, Texas A&M University, College Station, Texas.
Yang ShenDepartment of Electrical and Computer Engineering, Texas A&M University, College Station, Texas.ORCID 0000-0002-1703-7796
Aditi GargDepartment of Computational and Data Sciences, Indian Institute of Science, Bengaluru, India.
Debnath PalDepartment of Computational and Data Sciences, Indian Institute of Science, Bengaluru, India.ORCID 0000-0002-3591-5978
Yao YuDepartment of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, Texas.
Chad D HuffDepartment of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, Texas.
Sean V TavtigianHuntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, Utah.ORCID 0000-0002-7543-8221
Erin YoungHuntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, Utah.
Susan L NeuhausenDepartment of Population Sciences, Beckman Research Institute of City of Hope, Duarte, California.
Elad ZivDivision of General Internal Medicine, Department of Medicine, Institute of Human Genetics, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California.
Lipika R PalInstitute for Bioscience and Biotechnology Research, University of Maryland, Rockville, Maryland.
Gaia AndreolettiDepartment of Plant and Microbial Biology, University of California, Berkeley, California.ORCID 0000-0002-0452-0009
Steven E BrennerDepartment of Plant and Microbial Biology, University of California, Berkeley, California.ORCID 0000-0001-7559-6185
Maricel G KannDepartment of Biological Sciences, University of Maryland, Baltimore, Maryland.ORCID 0000-0003-0116-3883

Funding

Functional Determinnats in G Protein-coupled ReceptorsR01GM066099 · NIGMS · BAYLOR COLLEGE OF MEDICINE · PI LICHTARGE, OLIVIER · 2003 to 2022
$7.5M
Comparative genomics of protein structure and functionR01GM079656 · NIGMS · BAYLOR COLLEGE OF MEDICINE · PI LICHTARGE, OLIVIER · 2007 to 2019
$4.3M
Germline and Tumor Genomic Analyses of Breast Cancer in LatinasR01CA184585 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI NEUHAUSEN, SUSAN L., ZIV, ELAD · 2014 to 2018
$4.2M
Unraveling molecular and system-level mechanisms of human disease-associated protein mutationsR35GM124952 · NIGMS · TEXAS ENGINEERING EXPERIMENT STATION · PI Yang Shen · 2017 to 2026
$2.9M
VAAST+: Tool for variant prioritization, risk assessment and disease-gene findingR01GM104390 · NIGMS · UNIVERSITY OF UTAH · PI JORDE, LYNN, YANDELL, MARK DOUGLAS · 2013 to 2017
$2.2M
Component 2 - Resource ProjectU41HG007346 · NHGRI · UNIVERSITY OF CALIFORNIA BERKELEY · PI BRENNER, STEVEN E · 2015 to 2017
$1.7M
AVA,Dx: Analysis of Variation for Association with DiseaseU01GM115486 · NIGMS · RUTGERS, THE STATE UNIV OF N.J. · PI BROMBERG, YANA · 2015 to 2018
$1.2M
AVA,Dx: Analysis of Variation for Association with DiseaseR01GM115486 · NIGMS · RUTGERS, THE STATE UNIV OF N.J. · PI BROMBERG, YANA · 2019 to 2019
$306k
Critical Assessment of Genome Interpretation ConferenceR13HG006650 · NHGRI · UNIVERSITY OF CALIFORNIA BERKELEY · PI BRENNER, STEVEN E · 2011 to 2018
$165k
Andrew Sabin Family Foundation Fellowships R01GM104390NCI NIH HHS R01 CA184585NHGRI NIH HHS R13 HG006650NHGRI NIH HHS U41 HG007346NIGMS NIH HHS R01 GM066099NIGMS NIH HHS R01 GM079656NIGMS NIH HHS R01 GM104390NIGMS NIH HHS R01 GM115486NIGMS NIH HHS R35 GM124952NIGMS NIH HHS U01 GM115486NIH HHS GM066099NIH HHS GM079656NIH HHS R01CA CA184585NIH HHS R13 HG006650NIH HHS R35GM124952NIH HHS U01GM115486
6 · The paper itself

Abstract

The availability of disease-specific genomic data is critical for developing new computational methods that predict the pathogenicity of human variants and advance the field of precision medicine. However, the lack of gold standards to properly train and benchmark such methods is one of the greatest challenges in the field. In response to this challenge, the scientific community is invited to participate in the Critical Assessment for Genome Interpretation (CAGI), where unpublished disease variants are available for classification by in silico methods. As part of the CAGI-5 challenge, we evaluated the performance of 18 submissions and three additional methods in predicting the pathogenicity of single nucleotide variants (SNVs) in checkpoint kinase 2 (CHEK2) for cases of breast cancer in Hispanic females. As part of the assessment, the efficacy of the analysis method and the setup of the challenge were also considered. The results indicated that though the challenge could benefit from additional participant data, the combined generalized linear model analysis and odds of pathogenicity analysis provided a framework to evaluate the methods submitted for SNV pathogenicity identification and for comparison to other available methods. The outcome of this challenge and the approaches used can help guide further advancements in identifying SNV-disease relationships.

Indexed as

Polymorphism, Single NucleotideAdultAgedBreast NeoplasmsCase-Control StudiesCheckpoint Kinase 2Computational BiologyComputer SimulationExome SequencingFemaleGenetic Predisposition to DiseaseHispanic or LatinoHumansLinear ModelsMiddle AgedUnited StatesCheckpoint Kinase 2CHEK2 protein, humanbreast cancerCAGICHEK2Hispanic womenSNV

Identifiers

PMID31241222
PMCPMC6744287

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.